Genmab AS (Denmark) Executives
| GMAB Stock | DKK 1,378 11.50 0.83% |
Genmab AS employs about 1.6 K people. The company is managed by 23 executives with a total tenure of roughly 132 years, averaging almost 5.0 years of service per executive, having 67.83 employees per reported executive. Analysis of Genmab AS's management performance can provide insight into the firm performance.
| Jan Winkel CEO President and Chief Executive Officer |
| Tahamtan Ahmadi President Executive Vice President, Chief Medical Officer, Head of Experimental Medicines |
Genmab |
Genmab AS Management Team Effectiveness
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Genmab AS Workforce Comparison
Genmab AS is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 102,971. Genmab AS claims roughly 1,560 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38. Genmab AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genmab AS Price Series Summation is a cross summation of Genmab AS price series and its benchmark/peer.
Genmab AS Notable Stakeholders
A Genmab AS stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Genmab AS often face trade-offs trying to please all of them. Genmab AS's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Genmab AS's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jan Winkel | President and Chief Executive Officer | Profile | |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer, Head of Experimental Medicines | Profile | |
| Anthony Mancini | Chief Operating Officer, Executive Vice President | Profile | |
| Martine Vugt | Senior Vice President - Chief of Staff | Profile | |
| Birgitte Stephensen | Senior Vice President IPR & Legal | Profile | |
| Pernille Erenbjerg | Independent Director | Profile | |
| Jonathan Peacock | Independent Director | Profile | |
| Marisol Peron | Corporate Vice President Communications and Investor Relations | Profile | |
| Birgitte MSc | Ex Officer | Profile | |
| Daniel Bruno | Director, Employee Representative | Profile | |
| Peter Kristensen | Director, Employee Representative | Profile | |
| Deirdre Connelly | Independent Deputy Chairman of the Board | Profile | |
| Judith Klimovsky | Executive Vice President Chief Development Officer | Profile | |
| Paolo Paoletti | Independent Director | Profile | |
| Judith MD | Exec Officer | Profile | |
| Anders Pedersen | Non-Independent Director | Profile | |
| Rolf Hoffmann | Independent Director | Profile | |
| Anthony Pagano | Senior Vice President Global Finance and Corporate Development | Profile | |
| Michael Bauer | Senior Vice President Head of Operations R&D | Profile | |
| Andrew Carlsen | VP Director | Profile | |
| Peter Ros | Sr Accounting | Profile | |
| Mijke Zachariasse | Director, Employee Representative | Profile | |
| Rima Nassar | Director, Employee Representative | Profile |
About Genmab AS Management Performance
The success or failure of an entity such as Genmab AS often depends on how effective the management is. Genmab AS management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genmab management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genmab management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark.
Genmab AS Workforce Analysis
Traditionally, organizations such as Genmab AS use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genmab AS within its industry.Genmab AS Manpower Efficiency
Return on Genmab AS Manpower
| Revenue Per Employee | 5.4M | |
| Revenue Per Executive | 368.8M | |
| Net Income Per Employee | 1.9M | |
| Net Income Per Executive | 130.8M |
Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.